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Abstract
Background: Glycation of high-density lipoprotein (HDL) decreases its ability to induce cyclooxygenase-2 (COX-2)
expression and prostacyclin I-2 (PGI-2) release in endothelial cells. Whether lipid content of HDL, especially
sphingosine-1-phosphate (S1P), plays any specific role in restoring the protective function of HDL in type 2 diabetes
mellitus (T2DM) is still unknown.
Methods and results: Immunochemical techniques demonstrated that glycated HDL loses its protective function of
regulating COX-2 expression compared with diabetic HDL. We proved that the lipid content, especially phospholipid
content differed between diabetic HDL and glycated HDL. Levels of HDL-c-bound S1P were increased in T2DM
compared with control subjects as detected by UPLC-MS/MS (HDL-c-bound S1P in control subjects vs. T2DM:
309.1 ± 13.71 pmol/mg vs. 382.1 ± 24.45 pmol/mg, P < 0.05). Additionally, mRNA levels of S1P lyase enzymes and
S1P phosphatase 1/2 were decreased in peripheral blood by real-time PCR. Antagonist of S1P receptor 1 and 3
(S1PR1/3) diminished the functional difference between apoHDL&PL (HDL containing the protein components and
phospholipids) and diabetic apoHDL&PL (diabetic HDL containing the protein components and phospholipids).
With different doses of S1P reconstituted on glycated HDL, its function in inducing the COX-2 expression was
restored to the same level as diabetic HDL. The mechanism of S1P reconstituted HDL (rHDL) in the process of
regulating COX-2 expression involved the phosphorylation of ERK/MAPK-CREB signal pathway.
Conclusion/Significance: S1P harbored on HDL is the main factor which restores its protective function in endothelial
cells in T2DM. S1P and its receptors are potential therapeutic targets in ameliorating the vascular dysfunction in T2DM.
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Introduction
Diabetes mellitus is a systemic metabolic disease and a
major risk factor for the development of atherosclerosis
[1,2]. Hyperglycemia causes alterations in lipid metabolism
which bring about a series of adverse effects, includ-
ing enhanced HDL clearance, decreased apoA-1 tran-
scription and accelerated HDL glycation [3,4]. These
dramatically altered lipid metabolic changes can pro-
mote atherosclerosis [5,6].
Native HDL has protective role in inducing cyclooxyge-
nase-2 (COX-2) expression and prostacyclin I-2 (PGI-2)
release in endothelial cells [7]. PGI-2 is the major COX
catalyzed product which is metabolized from arachidonic
acid (AA) and plays a protective role in the macrovascular
endothelium [7,8]. Previous studies have shown that the
lipid component of HDL can induce COX-2 expression
and PGI-2 release, especially sphingosine-1-phosphate
(S1P) [9]. S1P is primarily carried on HDL in plasma and
has many biological functions, such as ability to promote
vasodilation, vasoconstriction, and angiogenesis, protect
against ischemia/reperfusion injury, and inhibit/reverse
atherosclerosis [10]. The level of S1P is controlled by two
pathways, dephosphorylation of S1P regenerating sphingo-
sine by S1P-specific phosphatases (SGPP), and the other is
the irreversible cleavage by sphingosine-1-phosphate lyase
(SPL) [11-14].
Non-enzymatic glycation is a common modification
that occurs in type 2 diabetes mellitus (T2DM), which
could impair protein function [15,16]. Previous studies
showed that non-enzymatic glycation of HDL impairs its
anti-inflammatory function and vascular protective ef-
fects [17-19]. Diabetic HDL could also down-regulate
expression of SR-BI causing a dysfunction in prolifera-
tion and migration of endothelial cells [20]. Previous
studies have shown alteration of sphingosine metabolism
in diabetes mellitus [21-23], so in this study, we focused
on the effect of the lipid component of HDL after glyca-
tion impairment. We recently proved that HDL-
associated S1P was increased in T2DM than healthy vol-
unteers [24]. In this work, we attempt to elucidate the
mechanism of S1P’s protective function in inducing
COX-2 expression and PGI-2 release.
Methods
Ethical approval
Healthy control subjects and patients with type 2 dia-
betes were recruited following informed consent. Hu-
man umbilical vein endothelial cells (HUVECs) were
obtained by collagenase digestion of umbilical cords
which were donated by the volunteers after written in-
formed consent. The study was approved and supervised
by the Institutional Review Board and Ethics Committee
of Peking University First Hospital (Beijing, China).
Chemical agents
S1P, C17-D-erythro-sphingosine-1-phosphate (C17-sph)
and the antagonist of S1PR1 and S1PR3 were purchased
from Avanti polar lipids (Alabama, USA). The antibodies
for western blot against phospho-extracellular regulated
kinase (ERK) 1/2 and cAMP-response element binding
protein (CREB) were purchased from Cell Signal Technology,
Danvers, MA. The antibodies of phospho-p38 mitogen-
activated protein kinase (MAPK), p38 MAPK and β-actin
were purchased from Santa Cruz Biotechnology, Santa Cruz,
CA. Antibody against COX-2 and competitive enzyme im-
munoassay kit for 6-keto PGF1α were from Cayman
Chemical (Michigan, IL). Horseradish peroxidase (HRP)-
goat-anti-rabbit IgG and HRP-goat-anti-mouse IgG were
purchased from MBL (Nagoya, Japan). Endothelial cell
medium (ECM) was purchased from ScienCell Research
Laboratories (Carlsbad, CA).
Subjects
Healthy volunteers and patients underwent physical exa-
mination, laboratory tests and ultra-sound examination
of the large arteries. The patients were all first diagnosed
with T2DM in accordance with international standards;
fasting plasma glucose (FPG) ≥ 7.0 mmol/L and glycated
hemoglobin (HbA1c) greater than 6.5%. The patients
were all first diagnosed in the hospital before initiation
of treatment. The healthy subjects had no family history
of diabetes, and they had normal FPG level and normal
glucose tolerance. Allowing the criteria above, 15 T2DM
and 15 healthy patients were recruited. The detailed
information of the recruited patients and healthy volun-
teers has been described in a previous study [24].
Cell culture
Human umbilical vein endothelial cells (HUVECs) were
obtained by collagenase treatment of umbilical cord vein
as described previously [25]. Cells were cultured on
gelatin-coated dishes and propagated in endothelial cell
medium supplemented with 5% FBS and endothelial
cells were grown at 37°C in an incubator with humidi-
fied air containing 5% CO2. HUVECs were harvested
when cells reached 70–80% confluent and passages three
to fifty were used.
Blood collection and HDL isolation
The fresh blood from T2DM and healthy volunteers was
drawn after overnight fasting into EDTA-Na2 vacuum
tubes. Plasma was separated by centrifuging at 2,500
rpm at 4°C for 15 minutes. HDL (1.063-1.210 g/ml) was
isolated by ultracentrifugation as described previously
[26]. HDL2 (1.063 < d < 1.125 g/ml) and HDL3 (1.125 <
d < 1.21 g/ml) were isolated by sequential ultracentrifu-
gation as previously described [27]. HDL sub fractions
were dialyzed against saline/EDTA (150 mM NaCl, 300
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μM EDTA, pH 7.4), sterilized by filtering through a 0.22
μm membrane, and stored at 4°C until needed. The
HDL was used within a month after isolation. The purity
of the HDL was confirmed by SDS-PAGE and western
blot using goat anti-apoA-I polyclonal antibody (Dia-
Sorin, Stillwater, OK) and quantified through the meas-
urement of apoA-I content by nephelometry (Dimension
XPand, Dade Behring, Germany). Equal concentration of
apoA-1 from isolated HDL was used for cell treatments
and S1P level determination.
Modification, selected delipidation and reconstitution
of HDL
HDL was incubated in glucose/phosphate-buffer saline
(PBS) buffer with butylated hydroxytoluene (BHT) (the
final concentration of glucose is 25 mmol/L) at 37°C for
7 days in vitro [17]. During this procedure, the oxidation
levels of modified HDL were measured (Additional file 1:
Figure S1). After HDL was dialyzed with PBS, glycated
HDL was used for cell experiments and reconstitution.
Selective delipidation was achieved as described previ-
ously. HDL was agitated with di isopropyl ether in a ratio
of 1:2 (vol/vol) at 4°C for 24 h [28]. After extraction, the
mixture was centrifuged at 2,000 rpm for 5 minutes to
separate the aqueous and organic phase. Apo HDL&PL
to (HDL containing the protein components and the
phospholipids) was collected in the aqueous phase and
PL-depleted HDL-lipids (the lipid component of HDL ex-
cept for the phospholipids) in the organic phase. Alterna-
tively, HDL was agitated with a mixture of butanol and di
isopropyl ether (vol/vol, 40:60) in a ratio of 1:2 (vol/vol)
for 30 minutes at the room temperature. After centrifuga-
tion we collected apoHDL (HDL containing the protein
components only) in aqueous phase and HDL-lipids (all
lipid component of HDL) in organic phase. ApoHDL&PL
and apoHDL were filtered before use. Reconstituted
HDL (rHDL) was made by adding S1P to glycated HDL
at the desired concentration and then mixed by rotation
overnight at 4°C for further usage [29]. The levels of
S1P used for reconstituting were nearly equal to the
S1P we detected on reconstituted HDL (Additonal file 1:
Figure S2).
S1P extraction and detection by UPLC-MS/MS
UPLC-MS/MS technique was employed to measure the
levels of HDL-associated S1P as previously described. Serum
samples mixed with internal standard C17-sph (50 μl of
1000 μg/L) was precipitated by methanol at the volume ra-
tio of 1:4. After centrifugation at 12,000 rpm for 15 minutes,
the supernatant was collected for UPLC-MS/MS analysis
performed by a Waters ACQUITY UPLCTM system as de-
scribed previously [24]. Waters ACUITY UPLC BEH Phenyl
column (1.8 μm; 2.1 mm× 100 mm) was selected for chro-
matographic separation. The injection volume was 5 μL.
Methanol (A) and 0.5% formic acid in ultrapure water (B)
were used as mobile phases. The gradient started at 10% A
and then increased linearly to 60% in 6 minutes, and then
to 100% at 6 minutes and kept for 2 minutes, followed by a
decrease to initial conditions of 10% A and held for 2
minutes to allow for equilibration. The flow rate was 0.3
mL/min. The column was maintained at 40°C, and the
sample room temperature was 10°C.
Real-time PCR assay for SPL and SGPP1/2
Real-time PCR was performed to determine mRNA levels
of SPL and SGPP1/2 from peripheral blood of the patients
and healthy volunteers. Total RNA was extracted using the
TRIzol reagent (Invitrogen, USA) and reverse transcription
was performed using an RT-PCR kit (TransGen Biotech,
China). Real-time experiments were conducted on a DNA
Engine Opticon System (MJ research Inc, USA) using SYBR
Green PCR Master Mix kit in triplicate specific primers.
The sequences of primers to determine the expression of
the target gene were as follows: SPL [5’-CTTGATG
CACTTCGGTGAGA-3’ (forward); 5’-TCCACCCCTTAG
CAGTCATC-3’ (reverse)], SGPP1 [5’-ACCGCCATCCCC
ATTTCT-3’ (forward); 5’-AGGAATCCAGCAATAATATC
CAG-3’ (reverse)], SGPP2 [5’-gTATTATACTCATGGTTC
AAGGTG-3’ (forward); 5’-GTGTAGGTAACAAACTTG
TAAGG-3’ (reverse)] and Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) [5’-CGGAGTCAACGGATTTGG
TCGTAT-3’ (forward); 5’-AGCCTTCTCCATGGTGGTGA
AGAC-3’ (reverse)]. The PCRs consisted of 5 min at 95°C
followed by 40 cycles of denaturation for 30 sec at 95°C,
annealing for 30 sec at 56°C and a primer extension for 30
sec at 72°C. The comparative CT method was used to
quantify the expression of SPL, SGPP1 and SGPP2 using
GAPDH as the normalized control.
ELISA: quantitation of 6-keto PGF1α
PGI-2 is non-enzymatically hydrated to 6-keto PGF1α and
estimation of systemic PGI-2 production has often been
assessed by measurement of 6-keto PGF1α [30]. The cell
culture supernatants were collected after centrifugation at
3000 rpm for 15 minutes. For accurate measurement of
PGI-2 production, 6-keto PGF1α in cell culture superna-
tants were determined using enzyme immunoassay kit
(Cayman Chemical). The final results were normalized to
cell protein concentration.
Western blotting and EMSA
Western blot analysis was performed as described pre-
viously [31], cells were washed twice with cold 1X PBS
and lysed on ice for 30 min in lysis buffer. The lysates
were subjected to centrifugation at 12,000 rpm for 15
min at 4°C and the supernatant was utilized for analysis.
Protein concentrations were determined using BCA me-
thod. The boiled samples were loaded on Ready SDS-10%
Tong et al. Cardiovascular Diabetology 2014, 13:82 Page 3 of 10
http://www.cardiab.com/content/13/1/82
PAGE gels and used for Western blot analysis with the
protein- specific antibody. HRP- labeled secondary anti-
body was used for detection of signal by electrochemilu-
minescence from Pierce (California, USA).
DNA-protein binding reactions were performed by in-
cubating nuclear extracts with specific CREB-CIE (cis-
inducible element) DNA binding. Polyclonal anti-CREB
antibody was added to the reaction mixture containing
the labeled probe. EMSA was performed as previously
described [32].
For EMSA assay, 10 μg nuclear protein was used with
15 fmol of HRP-end-labeled double stranded oligonucle-
otides in mixed nuclear extraction from HUVEC after
treated with HDL as described above. The sequence of
oligonucleotide containing CREB was: 5’-AGA GAT
TGC CTG ACG TCA GAC AGC TAG-3. Oligonucleo-
tides were end-labeled with HRP polynucleotide kinase
and purified on G-50 columns (Roche Diagnostics). The
DNA binding reaction of HRP labeled double-stranded
oligonucleotides was performed at room temperature for
20 min, according to the manufacturer's protocol. Elec-
trophoretic mobility shift assays were performed with
the Light Shift Chemiluminescent Kit from Pierce,
according to the manufacturer's recommendations.
Statistical analyses
All experiments were repeated in triplicate if not men-
tioned. Data are presented as mean ± SEM unless indi-
cated otherwise. Differences were compared with two-
tailed Student’s t-test or one-way ANOVA using Graph-
Pad Prism software. p < 0.05 was considered statistically
significant.
Results
Lipid component of diabetic HDL improved the
up-regulation of COX-2 expression and PGI-2 release in
endothelial cells
To test whether the glycation modification impaired
HDL function in endothelial cells, we used native HDL
and non-enzymatically glycated HDL treated with
HUVECs at the final concentration of 30 μg/ml for 6
hours. Glycated HDL failed to induce COX-2 expression
(Figure 1A). Compared with glycated HDL, the dia-
betic HDL showed significantly increased induction of
COX-2 expression (Figure 1B). To eliminate the dif-
ferences in lipid component, delipidated HDL was
used to treat HUVECs and the delipidated apoHDL regu-
lated COX-2 expression slightly more than delipidated
diabetic apoHDL. Both apoHDL and diabetic apoHDL
partially lost the ability in up-regulating COX-2 expression
(Figure 1C), which suggests that such effects are in part
mediated by lipid component instead of protein. The
selectively delipidated HDL, apoHDL&PL were used to
incubate with HUVECs at the final protein concentration
of 30 μg/ml for 6 hours. Diabetic apoHDL &PL re-
stored the effects of inducing COX 2 expression com-
pared with apoHDL&PL (Figure 1D), which implies that
the phospholipid (PL) component was essential for
these effects.
S1P levels are increased in lipid component of HDL in
diabetics compared to controls
To investigate the S1P level in plasma and HDL, we ex-
amined samples from 15 T2DM patients and control
subjects using UPLC-MS/MS. As S1P in plasma was
mainly bound to HDL-C, we normalized the levels of
total plasma S1P to plasma HDL-C, which gave us the
level of HDL-bound S1P. There was an increased HDL-
C-normalized level of S1P in diabetes mellitus compared
with control subjects (Figure 2A, control subjects vs.
T2DM: 309.1 ± 13.71 pmol/mg vs. 382.1 ± 24.45 pmol/mg,
Figure 1 The phospholipids component of HDL from T2DM
enhanced COX-2 expression and PGI-2 release. A-B: glycated
HDL (equal to 30 μg/ml of HDL) loss its function in regulation COX-2
expression compared with N-HDL (A) and diabetic HDL (equal to
30 μg/ml of HDL) has more increased COX-2 expression than gly-
cated HDL (equal to 30 μg/ml of HDL) (B). C-D: HDL only containing
protein components without any the lipid from N-HDL (N-apoHDL)
(equal to 30 μg/ml of HDL) is more functional than it’s from diabetes
mellitus (D-apoHDL) (equal to 30 μg/ml of HDL) in regulating COX-2
expression (C) and the preservation of phospholipids and protein com-
ponents of HDL from type 2 diabetes mellitus, D-apoHDL&PL (equal to
30 μg/ml of HDL), reversed the function in regulating COX-2 ex-
pression compared with the control subjects, N-apoHDL&PL (equal to
30 μg/ml of HDL) (D). Each experiment was repeated three times.
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P < 0.05). The levels of S1P in HDL2 and HDL3 were deter-
mined. The results showed that the levels of S1P associated
with diabetic HDL3 were significantly higher than native
HDL3, and S1P in diabetic HDL2 and native HDL2 showed
no difference (Figure 2B, T2DM-HDL3 vs. control-HDL3:
189.7 ± 7.4 vs 230.9 ± 13.8 ng/mg, p < 0.01). The levels of
S1P harbored on diabetic HDL (Y axis) were decreased
with the increasing levels of HbA1c (Additional file 1:
Figure S3). To investigate the mechanism for increased
level of S1P from diabetic HDL, the expression of related
enzymes that degenerate S1P was examined. The mRNA
levels of SPL and SGPP 1/2 from peripheral blood was
detected by the method of real-time PCR. The level of
SPL was decreased 1.6 fold and the levels of SGPP1
and SGPP2 were also decreased 4.8 fold and 15.7 fold
separately in diabetes compared with control subjects
(Figure 2C).
S1P receptor 1 (S1PR1) and S1P receptor 3 (S1PR3)
antagonists diminished the effect of HDL derived lipids
S1PR1 and S1PR3, specific receptors of S1P, are mainly
located in the endothelial cells [14]. To investigate whe-
ther these two receptors were involved in this process,
the S1PR1 and S1PR3 antagonist, VPC23019 was pre-
incubated with the endothelial cells for 20 minutes at
the final concentration of 2 nmol/L. The inhibitor diminished
the effect of diabetic apoHDL&PL and apoHDL&PL in up-
regulating COX-2 expression and PGI-2 release. (Figure 3A,
B and C, apoHDL&PL vs. PBS, 933.4 ± 55.05 vs. 327.6 ±
61.80, pg ·ml-1 ·mg cellular protein-1, (P < 0.001) diabetic-
apoHDL&PL vs. HDL&PL, 1695 ± 92.95 vs. 933.4 ± 55.05,
pg ·ml-1 ·mg cellular protein-1, (P < 0.001); apoHDL&PL+
VPC vs. apoHDL&PL, 517.1 ± 134.4 vs. 933.4 ± 55.05,
pg · ml-1 · mg cellular protein-1, (P < 0.001); diabetic-
apoHDL&PL + VPC vs. diabetic-apoHDL&PL, 457.9 ±
70.28 vs. 1695 ± 92.95, pg · ml-1 · mg cellular protein-1,
(P < 0.001)). Therefore, the effects of S1P from diabetic
HDL were likely mediated through the S1P receptors,
S1PR1 and S1PR3.
Reconstitution of S1P on glycated HDL was as effective as
diabetic HDL in inducing COX-2 expression and PGI-2
release
We used different doses of free S1P for binding on HDL
particles incubated with HUVECs and expression of
COX-2 was induced by the reconstituted HDL in a
dose-dependent manner (Figure 4A). The reconstitu-
tion of S1P on glycated HDL restored the ability of indu-
cing COX-2 expression and PGI-2 release and was dose
dependent (Figure 4B). These results show that S1P re-
constituted on HDL can reverse the loss of function
caused by glycation modification.
Reconstituted HDL with addition of S1P on glycated HDL
activates the ERK/MAPK pathways
The signal transduction activated by COX-2 expression
involves the ERK/MAPK-CREB pathway (29). Three kinds
of HDL, native HDL, glycated HDL (G-HDL) and the
reconstituted HDL (rHDL, S1P added on glycated HDL)
were used to treat HUVECs respectively. The glycated
Figure 2 Levels of S1P and its related enzymes were detected
by UPLC-MS/MS and real-time PCR. Levels of HDL-bound S1P
were significantly increased in diabetes mellitus than control
subjects. A-B: S1P level was normalized by HDL-c in plasma between
control subjects and T2DM (A), levels of diabetic HDL3- associated
S1P were increased compared with native HDL3-associated S1P (B).
*P < 0.05 vs. healthy group. The levels of mRNA involved in S1P
metabolism was measured by real-time PCR. C: The mRNA level of
SPL and SGPP1/2 was detected in T2DM and control subjects.
Mann–Whitney U test. Bars show medians. *p < 0.05.
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HDL was utilized to generate rHDL to reflect the in-
creased glycation to HDL in subjects with T2DM. rHDL
showed similar function when compared with native
HDL, while the G-HDL failed to activate the signaling
pathway. rHDL showed the most effect in activation of
the pathway at each tested time point (Figure 5A, B
and C, P < 0.01), suggesting a selective effect of S1P
in mediating these effects. The phosphorylation was
triggered by the three types of HDL starting at 5 mi-
nute and reached the peak at 15 minutes, and
returned to baseline at 60 minutes. The effect of rHDL in
activation of the phosphorylation of ERK and MAPK was
reduced by the VPC23019 (Figure 5D, E and F) suggest-
ing that this effect was mediated by the S1P receptors.
Reconstituted HDL enhances the transcription factor
CREB binding on the cis-inducible element (CIE) DNA
Since ERK1/2 and MAPK were the modulators of the
CREB protein, we tested whether the three kinds of
HDL enhanced the nuclear transcription factor CREB
activity or not. rHDL and native HDL markedly in-
creased CREB phosphorylation, whereas G-HDL had a
considerably weaker effect and antagonist of S1PR1
and S1PR3 reduced effects of rHDL (Figure 6A). As
shown in Figure 6B, reconstituted HDL enhanced more
transcription factor binding on the CIE DNA than the
other two forms of HDL. The binding of CREB to the CIE
sequence disappeared with 50-fold and 100-fold excess of
unlabeled CIE DNA (cold probe), confirming the specifi-
city of CIE DNA binding. CREB binding with CIE as
CREB/CIE DNA complex got abolished when anti-CREB
antibody was added in the system. These results demon-
strate that extra S1P loading on glycated HDL induced
more transcription factor CREB binding on its CIE DNA
complex.
Discussion
Diabetes mellitus is associated with HDL dysfunction
which accelerated atherosclerosis, in which HDL particle
undergoes diverse structural modifications resulting in
significant changes in its composition and function [6].
In this study, we investigated one of the most common
modifications, glycation and a well-known bioactive lipid
molecule, S1P.
Figure 3 The up-regulation of COX-2 expression by diabetic
apoHDL&PL was blocked by VPC23019. The up-regulation of
COX-2 expression by diabetic apoHDL&PL was blocked by S1PR1
and S1PR3 antagonist (VPC23019). A-B: HUVECs were pre-incubated
with or without VPC 23019 (15 nmol/ml) for 20 minutes and further
separately stimulated with 30 μg/ml of N-apoHDL&PL or D-apoHDL&PL,
expression of COX-2 was assayed by Western blotting (A), the relative
protein expression was normalized by β-actin (B) and the production
of PGI-2 was determined by competitive ELISA (C). Data are expressed
as the means ± SEM of three independent experiments. Student’s t test.
*p < 0.05. ***p < 0.001.
Figure 4 S1P reconstituted on HDL repair the function of
glycated HDL in a dose dependent manner. A-B: S1P binding on
HDL can enhance the COX-2 expression (A) and S1P restores the
glycated HDL loss of function in inducing COX-2 expression (B) at 0.1 μM,
1 μM and 5 μM concentration of S1P (binding with 30 μg/ml HDL or
glycated HDL). Each experiment was repeated three times.
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Previous studies have shown that non-enzymic glyca-
tion was a common modification that appeared in
T2DM and this modification impaired HDL’s anti-
inflammatory and anti-oxidant roles [33]. In this study,
we explored the mechanism involved in the effect of S1P
in repairing the function of glycated HDL, like inducing
COX-2 expression and PGI-2 release. We have previ-
ously shown that the level of diabetic HDL-associated
S1P is increased compared with native HDL [25]. As the
following work of that research, we found out that in the
T2DM group, the level of S1P harbored on HDL in
T2DM patients decreased with the elevated level of
HbA1c. So we assumed that higher level of S1P on HDL
could serve as protective effects to the vascular endothe-
lial, but with the progress of T2DM, the level of S1P was
decreased and the function of it was also diminished. At
the same time, we tried to figure out the potential mech-
anism involved in the increased level of S1P associated
with diabetic HDL [25]. The explanation of the increased
level of diabetic HDL-associated S1P was related to its
Figure 5 Phosphorylation of ERK 1/2 and MAPK was induced by N-HDL, G-HDL, rHDL (G-HDL containing S1P). A-C: HUVECs were
incubated with 30 μg/ml of N-HDL, G-HDL, rHDL at each time point, 5 minute, 15 minute, 30 minute, and 60 minute. The activation of ERK1/2,
p38 MAPK was analyzed by Western blotting (black circles = N-HDL, black squares = G-HDL, black bars = rHDL). D-F: HUVECs were pre-incubated
with VPC 23019 (15 nmol/ml) for 20 minute and then treated with 30 μg/ml of N-HDL, G-HDL, rHDL at each time point, 5 minute, 15 minute, 30
minute, and 60 minute (black circles = N-HDL, black squares = G-HDL, black bars = rHDL + VPC). The activation of ERK1/2, p38 MAPK was analyzed
by Western blotting. Representative bands from three independent experiments were shown.
Tong et al. Cardiovascular Diabetology 2014, 13:82 Page 7 of 10
http://www.cardiab.com/content/13/1/82
levels of expression of key elimination enzymes. S1P is
generated by SphK1/2 from sphingosine and eliminated
by dephosphorylation and lyase reactions [34]. The de-
phosphorylation of S1P is catalyzed by the actions of
S1P-specific phosphatases, as well as by enzymes of the
nonspecific lipid phosphate phosphatase family (LPPs).
Each of these enzymes regenerates sphingosine which
can be rapidly re-phosphorylated, thereby restoring S1P
levels. In contrast to the phosphatases, SPL catalyzes an
irreversible cleavage reaction that provides global control
over circulating S1P levels and tissue S1P pools [14,15].
As the final enzyme in the sphingolipid degradation
pathway, SPL controls the only exit point for sphingo-
lipid intermediates and their flow into phospholipid
metabolism [34]. Thus, in addition to regulating S1P
levels, SPL is the gatekeeper of a critical node of lipid
metabolic flow. The SPL plays the key role in regula-
tion of the S1P level in plasma and recruitment back
to sphingosine and thereby influencing S1P-dependent
biological and pathological processes [24]. In our
study, we found SPL activity is decreased which per-
haps leads to the increased level of HDL-associated
S1P increased in T2DM [25]. Previous studies were
shown that S1P was preferentially associating with
HDL3 [35]. In our work, we confirmed that the in-
creasing the level of HDL3-associated S1P restores its
function similar to what is observed with HDL from
diabetic subjects. This suggests that perhaps in T2DM
the increased levels of SIP may be a compensatory
protective mechanism.
The role of S1P in atherosclerosis is complex, as it has
both pro- and anti-atherosclerotic properties as shown
in previous studies [36,37]. The endothelial system sets
up the first barrier for the blood vessels and HDL with
S1P plays the important role in this protective proced-
ure. S1P receptors are G-coupled receptors located on
endothelial membrane where S1PR1 and S1PR3 are
mainly located. So the increased level of S1P occurring
in diabetic HDL3 may have vascular protective effects.
The accumulation of the lipids on HDL, especially S1P,
compensates the functional loss and may exert the role
of protection by regulation of COX-2 expression and ac-
tivation of ERK/MAPK-CREB pathway.
In addition to increased risk of stroke, myocardial
infarction, and peripheral vascular disease, diabetics
suffer from a particularly aggressive form of athero-
sclerosis with greater in-hospital mortality following
myocardial infarction, a higher incidence of heart fail-
ure and stroke [6]. The prevention of complications
needs more focus.
Conclusions
The current study demonstrates that the increasing level of
S1P occurring in diabetic HDL3 have vascular protective
effects. The accumulation of the lipids on HDL, espe-
cially S1P, compensates the functional loss and may exert
the role of protection by regulation of COX-2 expression
and activation of ERK/MAPK-CREB pathway. Such in-
creased S1P concentration possibly results from the down-
regulation of its degeneration enzymes (SPL and SGPP).
Our work sheds more light on the intrinsic mechanism
behind the protective effects of HDL in diabetic disease
thus opening doors for new therpeutic targets. Since cur-
rently available drug use in clinical practice has not pro-
vided us with appreciable results, new targets and
insights are needed as soon as new disease mechanisms
are recognized. The S1P pathway activation provides a
potential site for future drug design.
Figure 6 The phosphorylation and activation of CERB was
induced by N-HDL, G-HDL, rHDL (G-HDL containing S1P).
A-C: HUVECs were incubated with 30 μg/ml of N-HDL, G-HDL,
rHDL at 15 minute and the activation of CREB was analyzed by
Western blotting, HUVECs were pre-incubated with VPC 23019
(15 nmol/ml) for 20 minute and further treated 30 μg/ml of N-HDL,
G-HDL, rHDL at 15 minute and the activation of CREB was analyzed
by Western blotting (A) and the activation of transcription factor CERB
at 15 minute was determined by EMSA (B). Each experiment was
repeated three times.
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Additional file
Additional file 1: Figure S1. Detection of MDA level and PON1 activity
in N-HDL and G-HDL by spectrophotometry. The differences of MDA level
and PON1 activity in the two groups have no statistical significance. Figure S2.
The level of S1P reconstituted on HDL (30 mg/ml) was detected by the
method of UPLC-MS (A). The levels of S1P we reconstituted were nearly
equal to the S1P we detected on reconstituted HDL. Figure S3. In the T2DM
group, levels of S1P harbored on HDL (Y axis) were decreased when
the levels of HbA1c (X axis) increased. The correlation coefficient R was
0.7574, P < 0.001.
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